Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 1783 results found since Jan 2013.
Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018
MMWR Surveill Summ. 2021 May 14;70(3):1-26. doi: 10.15585/mmwr.ss7003a1.ABSTRACTPROBLEM/CONDITION: Adults are at risk for illness, hospitalization, disability and, in some cases, death from vaccine-preventable diseases, particularly influenza and pneumococcal disease. CDC recommends vaccinations for adults on the basis of age, health conditions, prior vaccinations, and other considerations. Updated vaccination recommendations from CDC are published annually in the U.S. Adult Immunization Schedule. Despite longstanding recommendations for use of many vaccines, vaccination coverage among U.S. adults remains low.REPORTING PER...
Source: MMWR Surveill Summ - May 13, 2021 Category: Epidemiology Authors: Peng-Jun Lu Mei-Chuan Hung Anup Srivastav Lisa A Grohskopf Miwako Kobayashi Aaron M Harris Kathleen L Dooling Lauri E Markowitz Alfonso Rodriguez-Lainz Walter W Williams Source Type: research
Herpes Zoster Following Covaxin Receipt
CONCLUSION: It is evident that VZV reactivation is one of the untoward events of the COVID-19 vaccine. However, it is wise to do large epidemiologic studies to check how common herpes zoster is after the receipt of COVID-19 vaccine.PMID:34880682 | PMC:PMC8646222 | DOI:10.2147/IMCRJ.S345288
Source: Herpes - December 9, 2021 Category: Infectious Diseases Authors: Oumer Abdu Muhie Haylemariam Adera Eyob Tsige Aschalew Afework Source Type: research
Oral Herpes Zoster Infection Following COVID-19 Vaccination: A Report of Five Cases
In this report, five cases of oral HZ following COVID-19 vaccinations are presented. Four cases were observed on the hard palate (V2), and one case was found on the mandible (V3). Four patients did not receive any treatment for their oral HZ, but one patient also had skin reactions on her right orbit and ear and was thus treated with an antiviral drug. As these cases were seen during such a short period of time and in one practice, the relationship with the COVID-19 vaccination appears to be related.PMID:34909338 | PMC:PMC8663753 | DOI:10.7759/cureus.19433
Source: Herpes - December 15, 2021 Category: Infectious Diseases Authors: Hiroshi Fukuoka Nobuko Fukuoka Toshiro Kibe R Shane Tubbs Joe Iwanaga Source Type: research
Pattern of Skin Diseases in Geriatric Population: Our Year-Long Experience from Nepal
CONCLUSION: This study concludes that dermatitis, infections and pruritus are the most significant dermatological morbidities in our population. It highlights the need of zoster vaccine for our elderly population as it is not a part of the routine vaccination scheme in Nepal.PMID:34934727 | PMC:PMC8653744 | DOI:10.4103/idoj.IDOJ_65_21
Source: Herpes - December 22, 2021 Category: Infectious Diseases Authors: Shraddha Uprety Sangeeta Paudel Pratichya Thapa Source Type: research
Reactivation of herpes zoster after vaccination with an inactivated vaccine: A case report from Nepal
Clin Case Rep. 2021 Dec 7;9(12):e05188. doi: 10.1002/ccr3.5188. eCollection 2021 Dec.ABSTRACTCOVID-19 has been linked to a number of cutaneous symptoms in COVID-19 patients. Although herpes zoster (HZ) was the first sign of COVID-19 infection in several patients, cases of HZ after COVID-19 vaccination are rare. Here, we report a case of 51-year-old male patient with herpes zoster after Sinopharm (Vero cell) vaccination.PMID:34934501 | PMC:PMC8650754 | DOI:10.1002/ccr3.5188
Source: Herpes - December 22, 2021 Category: Infectious Diseases Authors: Sangam Shah Bikash Baral Rajan Chamlagain Hritik Murarka Yagya Raj Adhikari Basanta Sharma Paudel Source Type: research
Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
Ther Adv Vaccines Immunother. 2021 Nov 30;9:25151355211057479. doi: 10.1177/25151355211057479. eCollection 2021.ABSTRACTAn adjuvanted recombinant zoster vaccine (RZV) is licensed for the prevention of herpes zoster. This paper reviews its safety and reactogenicity. A pooled analysis of two pivotal randomized Phase-3 trials (NCT01165177, NCT01165229) in adults ?50 years found that more solicited adverse events (AEs) were reported with RZV than placebo. Injection site pain was the most common solicited AE (RZV: 78.0% participants; placebo: 10.9%). Grade-3 pain occurred in 6.4% of RZV and 0.3% of placebo recipients. Myalgia, ...
Source: Herpes - January 10, 2022 Category: Infectious Diseases Authors: Joseph Fiore Maribel Miranda Co-van der Mee Andr és Maldonado Lisa Glasser Phil Watson Source Type: research
